QUANTITATIVE RHOA Gly17Val ALLELE-SPECIFIC POLYMERASE CHAIN REACTION AND T-CELL CLONALITY ANALYSIS IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA

Introduction. Аngioimmunoblastic T-cell lymphoma (AITL) is a T-cell lymphoma, characterized by abundant polymorphocellular infiltrate of lymph nodes with the small number of tumor CD4⁺ T-cells. AITL could often be misdiagnosed as reactive processes and other lymphomas, including Hodgkin’s lymphoma. Molecular methods of determining clonality are used to confirm the diagnosis. TCR gene rearrangements detected in the lymph nodes may not coincide with those detected in the bone marrow (BM), blood or skin, that makes their interpretation difficult. Recently discovered point somatic RHOA (Ras homolog gene family, member A) Gly17Val mutation is present in 53–71 % of angioimmunoblastic T-cell lymphomas.

The aim of the study was to evaluate the number of RHOA Gly17Val mutated cells in different tissues of AITL patients and to correlate it with corresponding T-cell clonality results.

Materials and methods. TCRG and TCRB gene rearrangements were PCR-amplified according to BIOMED-2 standardized protocol and analyzed by capillary electrophoresis on ABI Prism 3130. Gly17Val mutation was analyzed by quantitative allele-specific (qAS) TaqMan Real-Time PCR assay. Lymph nodes (LN) and skin biopsies, blood and BM samples were studied for 40 patients with AITL.

Results. The clonal TCR gene rearrangements were found in 37 (92 %) of 40 patients in LN and in 26 (96 %) of 28 patients in BM, but they were not matched in length in LN and BM in 12 (46 %) of 26 patients. RHOA (Gly17Val) mutation in LN was revealed in 60 % (24 of 40) patients. Number of cells with RHOA mutation was highest in the LN (in average 26.7 % of the total cells), while in the BM RHOA mutation were undetectable (in 7 patients), or detected in 10 patients in a low quantity (in average 2 % of the total cells). Skin, blood and BM samples with the T-cell clonality peaks that differ from those found in the LN were also negative for the presence of cells having RHOA Gly17Val mutation. Also, in four patients we showed that clonal products in BM and blood that do not coincide with LN refer to CD8+ lymphocytes.

Conclusions. The results of the study demonstrate that the quantitative determination of cells with the mutation of RHOA Gly17Val must be taken into account in staging the disease and interpreting the results of T-cell clonality assay. Clonal cells with rearrangements not matching those identified for the LN should be considered reactive.

1. Swerdlow S.H., Campo E., Harris N.L. et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2008.

2. Vose J., Armitage J., Weisenburger D.; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer / T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26(25):4124–30. DOI: 10.1200/JCO.2008.16.4558. PMID: 18626005.

3. Weiss L.M., Jaffe E.S., Liu X.F. et al. Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood 1992;79(7):1789–95. PMID: 1373088.

4. Zettl A., Lee S.S., Rudiger T. et al. Epstein–Barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified. Am J Clin Pathol 2002;117(3):368–79. DOI: 10.1309/6UTXGVC0-12ND-JJEU. PMID: 11888076.

5. Dogan A., Attygalle A.D., Kyriakou C. Angioimunoblastic T-cell lymphoma. Br J Haematol 2003;121(5):681–91. DOI: 10.1046/j.1365-2141.2003.04335.x. PMID: 12780782.

6. Стефанов Д.Н., Ковригина А.М., Поддубная А.М. Новая концепция происхождения ангиоиммунобластной Т-клеточной лимфомы: от молекулярной биологии к терапии. Бюллетень СО РАМН 2011;31(2):14–9.[Stefanov D.N., Kovrigina A.M., Poddubnaya A.M. A new concept of of angioimmunoblastic T-cell lymphoma origin: from molecular biology to therapy. Bulleten SO RAMN = Bulletin ofthe SB RAMS 2011;31(2):14–9.(In Russ.)].

7. Brüggemann M., White H., Gaulard P. et al. Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98–3936. Leukemia 2007;21(2):215–21. DOI: 10.1038/sj.leu.2404481. PMID: 17170730.

8. Lachenal F., Berger F., Ghesquières H. et al. Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients. Medicine (Baltimore) 2007;86(5):282–92. DOI: 10.1097/MD. 0b013e3181573059. PMID: 17873758.

9. Никитин Е.А., Сидорова Ю.В., Рыжикова Н.В. и др. Определение Т-клеточной клональности по гамма-цепи Т-клеточного рецептора: окончательные данные. Терапевтический архив 2006;78(7):52–7. [Nikitin E.A., Sidorova Yu.V., Ryzhikova N.V. et al. Determination of T-cell clonality by T-cell receptor gamma chain: final data. Terapevticheskiy arkhiv = Therapeutic archive 2006;78(7):52–7. (In Russ.)].

10. Сидорова Ю.В., Никулина Е.Е., Чернова Н.Г. и др. Определение клональности методом ПЦР при ангиоиммунобластной Т-клеточной лимфоме. Клиническая онкогематология. Фундаментальные исследования и клиническая практика 2014;7(2):192–6. [Sidorova Yu.V., Nikulina E.E., Chernova N.G. et al. PCRbased clonality detection in angioimmunoblast T-cell lymphoma. Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaya praktika = Clinical Oncohematology. Basic Research and Clinical Practice 2014;7(2):192–6. (In Russ.)].

11. Zaki M.A., Wada N., Kohara M. et al. Presence of B-cell clones in T-cell lymphoma. Eur J Haematol 2011;86(5): 412–9. DOI: 10.1111/j.1600-0609.2011.01597.x. PMID: 21362051.

12. Attygalle A., Al-Jehani R., Diss T.C. et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 2002;99(2):627–33. DOI: 10.1182/blood.V99.2.627. PMID: 11781247.

13. Tan B.T., Warnke R.A., Arber D.A. The frequency of B- and T-cell gene rearrangements and Epstein-barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations. J Mol Diagn 2006;8(4):466–75. DOI: 10.2353/jmoldx.2006.060016. PMID: 16931587.

14. Sakata-Yanagimoto M., Enami T., Yoshida K. et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 2014;46(2):171–5. DOI: 10.1038/ng.2872. PMID: 24413737.

15. Palomero T., Couronné L., Khiabanian H. et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014;46(2):166–70. DOI: 10.1038/ng.2873. PMID: 24413734.

16. Kataoka K., Ogawa S. Variegated RHOA mutations in human cancers. Exp Hematol 2016;44(12):1123–9. DOI: 10.1016/j.exphem.2016.09.002. PMID: 27693615.

17. Nakamoto-Matsubara R., SakataYanagimoto M., Enami T. et al. Detection of the G17V RHOA mutation in angioimmunoblastic T-cell lymphoma and related lymphomas using quantitative allele-specific PCR. PLoS One 2014;9(10):e109714. DOI: 10.1371/journal.pone.0109714. PMID: 25310466.

18. Saoudi A., Kassem S., Dejean A. et al. Rho-GTPases as key regulators of T-lymphocyte biology. Small GTPases 2014;5:e28208. DOI: 10.4161/sgtp.28208. PMID: 24825161.

19. Сидорова Ю.В., Сорокина Т.В., Бидерман Б.В. и др. Определение минимальной остаточной болезни у больных В-клеточным хроническим лимфолейкозом методом пациент-специфичной ПЦР. Клиническая лабораторная диагностика 2011;12:22–4.[Sidorova Yu.V., Sorokina T.V., Biderman B.V. et al. Minimal residual disease detection in patients with B-cell chronic lymphocytic leukemia by patientspecific PCR. Klinicheskaya laboratornaya diagnostika = Clinical laboratory diagnostics 2011;12:22–4. (In Russ.)].

20. Sidorova J.V., Biderman B.V., Nikulina E.E. et al. A simple and efficient method for DNA extraction from skin and paraffin-embedded tissues applicable to T-cell clonality assays. Exp Dermatol 2012;21(1):57–60. DOI: 10.1111/j.1600-0625.2011.01375.x. PMID: 21995276.

21. Dongen J.J., Langerak A.W., Bruggemann M. et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98–3936. Leukemia 2003; 17(12):2257–317. DOI: 10.1038/sj.leu.2403202. PMID: 14671650.

22. Lukes R.J., Tindle B.H. Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin»s disease. N Engl J Med 1975;292(1):1–8. DOI: 10.1056/NEJM197501022920101. PMID: 1078547.

23. Frizzera G., Moran E.M., Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet 1974;1(7866):1070–3. DOI: 10.1016/S0140–6736(74) 90553–4. PMID: 4135245.

24. Сидорова Ю.В., Чернова Н.Г., Рыжикова Н.В. и др. Клональные реаранжировки и опухолевые клоны при периферической Т-клеточной лимфоме. Acta Naturae (русскоязычная версия) 2015;7(3):130–40. [SidorovaYu.V.,Chernova N.G., Ryzhikova N.V. et al. Clonal rearrangements and Malignant Clones in Peripheral T-cell Lymphoma. Acta Naturae (Russian version) 2015;7(3): 130–40. (In Russ.)]. PMID: 26483968.

25. Чернова Н.Г., Виноградова Ю.Е., Сидорова Ю.В. и др. Длительные режимы цитостатической терапии ангиоиммунобластной Т-клеточной лимфомы. Клиническая онкогематология. Фундаментальные исследования и клиническая практика 2014;7(1):57–62.[Chernova N.G., Vinogradova Yu.E., Sidorova Yu.V. et al. Prolonged chemotherapy for angioimmunoblastic T-cell lymphoma. Klinicheskaya onkogematologiya. Fundamentalnye issledovaniya i klinicheskaya praktika = Clinical Oncohematology. Basic Research and Clinical Practice 2014;7(1):57–62. (In Russ.)].